E-cigarettes vs nicotine patches: are either adequate to support pregnant smokers?

ruvim-noga-pazM9TQJ2Ck-unsplash

Did you know that maternal smoking during pregnancy increases the risk of smoking uptake amongst the offspring when they reach adolescence? (Niemela et al. 2017, Biederman et al. 2014) This is in addition to many other health problems both for women and their offspring, such as ectopic pregnancy and low birth weight (Saygın Avşar et al., 2021).

Smoking during pregnancy is a major public health issue, especially in high-income countries; for example, in the UK, around 10% of pregnant women smoke during pregnancy (NHS Digital 2022). Not only that but also women from disadvantaged backgrounds are more likely to smoke during pregnancy, and thus it is also a health inequality problem (Smedberg et al. 2013).

Currently, the only biological treatment recommended for pregnant women is nicotine replacement therapy which is often provided in the form of nicotine patches or chewing gums. However, nicotine replacement therapy has limited or no impact on quit rates during pregnancy (Coleman et al. 2012). Thus, we need novel approaches to help pregnant women who would like to quit smoking.

Could e-cigarettes offer an alternative? Trying to answer this, Hajek et al. (2022) compared e-cigarette use to nicotine replacement therapy to understand whether it is safe and effective as a smoking cessation aid for pregnant women.

10% of women in the UK smoke during pregnancy which can lead to adverse health problems for both mother and child. Could e-cigarettes be successful in achieving smoking cessation in pregnant women?

10% of women in the UK smoke during pregnancy which can lead to adverse health problems for both mother and child. Could e-cigarettes be successful in achieving smoking cessation in pregnant women?

Methods

This was a randomised controlled trial conducted across 23 NHS sites in England and Scotland. In the intervention group, 576 women used e-cigarettes for at least four weeks, while 569 women in the control group used nicotine patches. Women’s smoking status was measured four weeks after the start of the trial and at the end of pregnancy. Smoking status was measured through self-report, and where possible triangulated with saliva samples and carbon monoxide readings.

Results

The key characteristics of the women were similar in the intervention and control groups; the median age was 27, on average participants were around 15.7 weeks pregnant, consumed 10 cigarettes daily (median value), and around half had tried e-cigarettes before.

At the end of pregnancy, 20% in the e-cigarette group and 14% in the nicotine patch group stated that they were not smoking. Usable saliva samples were obtained from 108 women (66 e-cigarette users and 42 nicotine patch users). These samples showed that 39 women among the e-cigarette users and 25 nicotine patch users were abstinent from smoking. In the statistical analysis, there was no difference between these two groups.

However, the researchers realised that five women in the control arm who were allocated to use nicotine patches only had in fact used e-cigarettes in addition to nicotine patches. When these five women were excluded from the analysis, the findings favoured e-cigarettes, showing that women who used e-cigarettes were 93% more likely to quit smoking by the end of pregnancy compared to those who used nicotine patches.

The researchers also looked at the birth outcomes and found that babies born to women in the e-cigarette group were 65% less likely to be low birth weight compared to the babies born to women in the nicotine patches group. Regarding the adverse events, there was no meaningful difference between both groups.

Women in this study had a clear preference for e-cigarettes, given that use of e-cigarettes was higher in the e-cigarettes group compared to the use of nicotine patches in the nicotine patches group. This was even though e-cigarette users had to pay for e-cigarette fillings themselves after the initial kit was provided while nicotine patches were prescribed.

Another important finding was that women who did not quit smoking entirely were 25% more likely to reduce the amount of smoking by 50% or more if they were using e-cigarettes compared to those using nicotine patches only. This is important because the higher number of cigarettes consumed, the higher the health risks.

"In a pre-specified sensitivity analysis excluding abstinent participants who used non-allocated products, e-cigarettes were more effective than patches (6.8% versus 3.6%; RR = 1.93, 95% CI: 1.14 to 3.26, P = 0.02)."

“In a pre-specified sensitivity analysis excluding abstinent participants who used non-allocated products, e-cigarettes were more effective than patches (6.8% versus 3.6%; RR = 1.93, 95% CI: 1.14 to 3.26, P = 0.02).”

Conclusions

This study shows that e-cigarettes might be more effective than nicotine replacement therapy in helping pregnant women who would like to quit smoking. E-cigarettes can also help pregnant women reduce smoking if they are not yet ready to quit entirely.

E-cigarettes were found to be more effective, and more favoured, than nicotine replacement therapy in helping pregnant women to quit smoking.

In this trial, e-cigarettes were found to be more effective, and more favoured, than nicotine replacement therapy in helping pregnant women to quit smoking.

Strengths and limitations

This study was a randomised controlled trial, which is considered the gold standard for measuring treatment effects in medicine and public health. The study included 1,140 pregnant women from across the UK and reported compliance and other important information, such as living with other smokers. In contrast to most smoking cessation studies in pregnant women, the impact on reducing smoking was measured, as well as quit rates.

However, there are some limitations that should be considered. The researchers did not report if the timing of the quit attempt affected smoking abstinence and birth outcomes, such as low birth weight. For instance, would the health benefits of quitting smoking differ if women in the nicotine patches group were more ahead in pregnancy compared to those in the e-cigarettes arm?

Despite the favourable results for e-cigarettes, the quit rates at the end of pregnancy were very low in both arms (7% vs 4%). One reason for this might be that around 60% of the participants in this study had other smokers at home, and previous studies have shown that pregnant women are less likely to quit smoking if they live with another smoker (Kia et al. 2017).

Finally, this study did not consider the long-term impacts of e-cigarettes and nicotine patches. It was previously shown that most women who quit smoking during pregnancy start smoking again (see a blog on a study by Jones et al., 2016).

Whilst this study showed favourable results for e-cigarettes, the quit rates at the end of pregnancy were very low in both arms - only 7% of those in the e-cigarette group and 4% in the nicotine replacement therapy group.

Whilst this study showed favourable results for e-cigarettes, the quit rates at the end of pregnancy were very low in both arms – only 7% of those in the e-cigarette group and 4% in the nicotine replacement therapy group.

Implications for practice

Currently, the only biological treatment offered for pregnant women who would like to stop smoking is nicotine patches, although it has been known that pregnant women do not like nicotine patches due to the adverse effects, such as nausea (Bowker et al. 2016, Campbel et al. 2020). The study findings suggest that e-cigarettes might be a safe and more effective alternative to nicotine patches for smoking cessation during pregnancy.

Currently, there is no support available for women who do not want to or are not yet ready to quit smoking entirely in the UK. This study shows that e-cigarettes can help those women reduce the number of cigarettes they smoke during pregnancy. This is important because the health risks increase with the increased amount of smoking, and women who smoke fewer cigarettes are more likely to quit entirely in the future.

Although this study suggests that e-cigarettes might be more effective than nicotine patches, the low levels of quit rates show that pregnant women who would like to quit need more support in addition to biological support. The evidence suggests that optimum interventions for pregnant women include providing long-term intense behavioural support, providing financial incentives contingent on quitting smoking and adopting a household approach (Morgan et al. 2015, also see a blog on the use of financial incentives for smoking cessation during pregnancy). A recent economic evaluation of hypothetical optimum interventions for pregnant women found that such interventions would be cost-effective and warrant attention in the UK (Saygın Avşar et al., 2022).

Pregnant women need more than just biological support to quit smoking, Optimum interventions include long-term intense behavioural support, financial incentives and a household approach to smoking cessation.

Pregnant women need more than just biological support to quit smoking, Optimum interventions include long-term intense behavioural support, financial incentives and a household approach to smoking cessation.

Statement of interests

Tuba Saygın Avşar’s (TSA) time is supported by National Institute for Health and Care Research (NIHR) Academic Research Collaboration North Thames and UCL Partners. The views expressed in this blog are those of the author and not necessarily those of the NIHR, the Department of Health and Social Care. TSA declares no conflicts of interest.

Links

Primary paper

Hajek, P., Przulj, D., Pesola, F. et al. Electronic cigarettes versus nicotine patches for smoking cessation in pregnancy: a randomised controlled trial. Nat Med 28, 958–964 (2022). https://doi.org/10.1038/s41591-022-01808-0.

Other references

Biederman J, Martelon M, Woodworth KY, Spencer TJ, Faraone SV. Is Maternal Smoking During Pregnancy a Risk Factor for Cigarette Smoking in Offspring? A Longitudinal Controlled Study of ADHD Children Grown Up. J Atten Disord. 2017 Oct;21(12):975-985. doi: 10.1177/1087054714557357. Epub 2014 Nov 21. PMID: 25416463.

Bowker, K., Campbell, K. A., Coleman, T., Lewis, S., Naughton, F., & Cooper, S. (2016). Understanding pregnant smokers’ adherence to nicotine replacement therapy during a quit attempt: a qualitative studyNicotine & Tobacco Research18(5), 906-912.

Campbell K, Coleman-Haynes T, Bowker K, Cooper SE, Connelly S, Coleman T. Factors influencing the uptake and use of nicotine replacement therapy and e-cigarettes in pregnant women who smoke: a qualitative evidence synthesis. Cochrane Database Syst Rev. 2020 May 22;5(5):CD013629. doi: 10.1002/14651858.CD013629

Coleman T., Cooper S., Thornton J. G., Grainge M. J., Watts K., Britton J., et al. A randomized trial of nicotine replacement therapy patches in pregnancyNew Engl J Med 2012; 366: 808– 18. doi: 10.1056/NEJMoa1109582

Fluharty M. Financial incentives for smoking cessation in pregnancy. The Mental Elf, 11th March 2015.

Jones, M., Lewis, S., Parrott, S., Wormall, S., and Coleman, T. (2016) Re-starting smoking in the postpartum period after receiving a smoking cessation intervention: a systematic review. Addiction, 111: 981– 990. doi:10.1111/add.13309.

Kia F, Tosun N, Carlson S, Allen S. Examining characteristics associated with quitting smoking during pregnancy and relapse postpartum. Addict Behav. 2018 Mar;78:114-119. doi: 10.1016/j.addbeh.2017.11.011.

Maynard O. Rates of restarting smoking after giving birth. The Mental Elf, 25th April 2016.

Morgan H, Hoddinott P, Thomson G, Crossland N, Farrar S, Yi D, et al. Benefits of Incentives for Breastfeeding and Smoking cessation in pregnancy (BIBS): a mixed-methods study to inform trial design. Health Technol Assess. 2015;19(30):1-564, https://www.ncbi.nlm.nih.gov/books/NBK285817/.

NHS Digital, Statistics on Women’s Smoking Status at Time of Delivery: England, 2022.

Niemelä S, Räisänen A, Koskela J, Taanila A, Miettunen J, Ramsay H, Veijola J. The effect of prenatal smoking exposure on daily smoking among teenage offspring. Addiction. 2017 Jan;112(1):134-143. doi: 10.1111/add.13533. Epub 2016 Sep 21. PMID: 27444807.

Saygın Avşar T, Jackson L, Barton P, Jones M, McLeod H. Towards optimum smoking cessation interventions during pregnancy: a household model to explore cost-effectiveness. Addiction. 2022. doi: 10.1111/add.15955. Epub ahead of print. PMID: 35603912.

Saygın Avşar T, McLeod H, Jackson L. Health outcomes of smoking during pregnancy and the postpartum period: an umbrella review. BMC Pregnancy Childbirth. 2021 Mar 26;21(1):254. doi: 10.1186/s12884-021-03729-1. PMID: 33771100; PMCID: PMC7995767.

Smedberg, J., Lupattelli, A., Mårdby, AC. et al. Characteristics of women who continue smoking during pregnancy: a cross-sectional study of pregnant women and new mothers in 15 European countries. BMC Pregnancy Childbirth 14, 213 (2014). https://doi.org/10.1186/1471-2393-14-213

Photo credits

Share on Facebook Tweet this on Twitter Share on LinkedIn Share on Google+
Mark as read
Create a personal elf note about this blog
Profile photo of Tuba Saygın Avşar

Tuba Saygın Avşar

Tuba Saygın Avşar is a Health Economist, working at the National Institute for Health and Care Institute (NICE) in the UK. Tuba provides scientific and technical advice to support the development of NICE guidelines, standards, and other products. This includes interpreting and evaluating clinical and economic evidence. She has in-depth expertise in applying appropriate and innovative health economics research methods to evaluate health, social care, and population health interventions and policies, focusing on national upscaling and implementation research. Tuba is especially interested in digital health innovations, AI-based technologies, smoking cessation interventions and implementation. Before joining NICE, Tuba worked at University College London and University of Birmingham. She has a PhD in health economics from the University of Birmingham, which evaluated smoking cessation interventions for pregnant women. She also holds two masters’ degrees from Swansea University and Suleyman Demirel University (Türkiye), focusing on topics related to Health Economics, Health Policy, and Healthcare Management. Any views expressed are of the authors not the affiliated institutions’.

More posts

Follow me here –